BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) — HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel vaccines, today joins the Guggenheim Securities 4 announced that it willth Annual Immunology and Neurology Day and Stifel Healthcare Conference. HIL-214, HilleVax’s Investigational Virus-Like Particle (VLP)-Based Vaccine for the Prevention of Moderate to Severe Norovirus-Associated Acute Gastroenteritis, and the Associated Ongoing Phase 2b Clinical Trial NEST-IN1 will be the topic of discussion at both events.
| Guggenheim Fireside Chat Details: | ||
| date: time: Moderator: HilleVax Participants: |
Monday, November 14, 2022 3:55 PM – 4:20 PM Eastern Daylight Time (EDT) Seamus Fernandez Robert Hershberg, MD, Ph.D., Chairman and Chief Executive Officer |
|
| To access the session, please contact your Guggenheim representative | ||
| Stifel presentation details: date: time: Moderator: HilleVax Participants: Webcast link: |
Wednesday, November 16, 2022 8:35am – 9:05am Eastern Daylight Time (EDT) Stephen Willie Robert Hershberg, MD, Ph.D., Chairman and Chief Executive Officer https://wsw.com/webcast/stifel74/hlvx/2126052 |
|
About HilleVax
HilleVax is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel vaccines. His first program, HIL-214, is a virus-like particle (VLP)-based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Globally, norovirus is estimated to cause over 700 million cases of AGE and 200,000 deaths annually, resulting in direct health system costs of over $4 billion and social costs of $60 billion annually. I’m here. The burden of norovirus falls disproportionately on young children and the elderly. For more information about HilleVax, please visit the company’s website at http://www.HilleVax.com.
contact:
Shane Maltby
IR@hillevax.com
+1-617-213-5054
